DALLAS--(BUSINESS WIRE)--EnLiSense CCM, a pioneer in non-invasive, real-time inflammatory biomarker monitoring, announces the initiation of multiple groundbreaking clinical studies in collaboration with top-tier medical institutions to further the management of Inflammatory Bowel Disease (IBD). Building on the momentum from the previous venture funding by the Crohn's and Colitis Foundation, EnLiSense CCM is partnered with premier medical institutions like the University of Chicago, Mount Sinai, University of Glasgow, and University of Texas Dallas to develop a decision-support tool for physicians and patients.
Patients and clinicians are now actively being enrolled in these studies, marking a pivotal phase in EnLiSense's journey towards revolutionizing chronic disease management. EnLiSense invites individuals interested in participating to learn more and join us by visiting IBDwearable.com.
The IBD Aware system, a cornerstone of EnLiSense's innovative approach, continuously monitors key inflammatory biomarkers by gently resting on a patient’s skin sampling just nano-liters of passive sweat. This non-invasive, wearable technology empowers both clinicians and patients with real-time data, facilitating personalized, data-driven, proactive management of chronic diseases like IBD.
Dr. Sriram Muthukumar, CEO of EnLiSense CCM, reflects on the early findings, stating, "The initial validation data is indeed very encouraging. We are beginning to uncover unforeseen circadian rhythms and other insightful patterns which are crucial for understanding IBD dynamics. Although it's still early days, these findings are a promising step towards a future where real-time monitoring can significantly enhance disease management."
Dr. Shalini Prasad, Chief Scientific Officer at EnLiSense CCM, envisions a profound impact on patients with chronic diseases. She remarks, "Our technology is poised to transform lives by enabling patients to monitor their disease activity in real-time, from the comfort of their homes. This not only fosters a proactive and personalized approach to disease management but also bridges the geographical gap between patients and physicians, making quality care accessible irrespective of distance."
The IBD Aware system is engineered to monitor key IBD biomarkers including Calprotectin, Tumor Necrosis Factor alpha (TNF-α), C-Reactive Protein (CRP), and Interleukin-6 (IL6), providing a comprehensive view of IBD disease activity. Beyond these, EnLiSense is actively engaged in research to extend the monitoring capabilities to other significant biomarkers such as Cortisol, Melatonin, Glucose, Interleukin-1 beta (IL1-β), Glial fibrillary acidic protein (GFAP), and Brain-derived neurotrophic factor (BDNF). This ongoing research underscores EnLiSense's commitment to broadening the understanding and management of chronic diseases through continuous innovation. EnLiSense CCM is at the forefront of transforming chronic disease management. We welcome patients, clinicians, and investors to join us on this exciting journey towards a healthier future.
About EnLiSense CCM
EnLiSense CCM is at the forefront of sweat sensor technology, creating real-time, non-invasive medical wearables that significantly enhance patient care in managing inflammation-related chronic health conditions. Our flagship products, IBD Aware and Corti are designed to provide actionable insights, fostering a proactive approach to individualized disease management for both patients and clinicians by providing decision-support tools that aid clinicians and patients in managing chronic diseases. These pioneering solutions underscore our commitment to elevating the standard of care through continuous innovation. Explore our offerings at CortiWearable.com and IBDwearable.com. For our terms and conditions, please visit our website.
